Montelukast Tarbis

Montelukast, the active ingredient in Montelukast Tarbis, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is employed in the maintenance treatment of asthma, relief of allergic rhinitis symptoms, and prevention of exercise‑induced bronchoconstriction in adults and children. GNH USA supplies Montelukast Tarbis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to control airway inflammation and allergic responses. - Asthma: reduces frequency of bronchospasm and improves overall control. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching. - Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Abdominal pain: occasional discomfort. - Nausea: transient episodes. - Dizziness: occasional light‑headedness.

Serious or Rare Side Effects: - Allergic reactions: rash, angioedema, or anaphylaxis. - Neuropsychiatric events: mood changes, depression, or suicidal thoughts. - Hepatic enzyme elevation: abnormal liver function tests. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy, consider the following safety measures. - Monitor for neuropsychiatric events: watch for mood changes or depression. - Assess hepatic function: dose adjustment may be needed in severe liver impairment. - Pregnancy considerations: risk category is unknown; discuss benefits and risks with a healthcare professional. - Concomitant CYP inducers: be aware that strong enzyme inducers can lower drug exposure. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Montelukast may interact with other medicines that affect its metabolism or pharmacodynamic profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin): may substantially reduce plasma concentrations. - Phenobarbital: can lower therapeutic levels. - Ketoconazole (strong CYP3A4 inhibitor): may increase exposure and risk of adverse effects.

Moderate Interactions (Monitor Closely): - Fluconazole (moderate CYP3A4 inhibitor): may modestly raise montelukast levels. - Gemfibrozil (CYP2C9 inhibitor): potential increase in drug exposure. - Warfarin: occasional reports of altered INR; monitor coagulation parameters.